Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Sarah Holstein, MD, PhD, University of Nebraska Medical Center, Omaha, NE, maps out the future of measurable residual disease (MRD) assessment in clinical trial practice and the current limitations of the method outside of a clinical trial context at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.